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Abstract Hepatic glycogen storage diseases (GSD) under-
score the intimate relationship between carbohydrate and lipid
metabolism. The hyperlipidemias in hepatic GSD reflect
perturbed intracellular metabolism, providing biomarkers in
blood to monitor dietary management. In different types of
GSD, hyperlipidemias are of a different origin. Hypertriglyc-
eridemia is most prominent in GSD type Ia and associated
with long-term outcome morbidity, like pancreatitis and he-
patic adenomas. In the ketotic subtypes of GSD, hypertriglyc-
eridemia reflects the age-dependent fasting intolerance, sec-
ondary lipolysis and increased mitochondrial fatty acid oxida-
tion. The role of high protein diets is established for ketotic
types of GSD, but non-traditional dietary interventions (like
medium-chain triglycerides and the ketogenic diet) in hepatic
GSD are still controversial and necessitate further studies.
Patients with these rare inherited disorders of carbohydrate
metabolism meet several criteria of the metabolic syndrome,
therefore close monitoring for cardiovascular diseases in age-
ing GSD patients may be justified.
Abbreviations
BMI Body mass index
CNGDF Continuous nocturnal gastric drip-feeding
CPT I Carnitine palmitoyltransferase I
EGP Endogenous glucose production
ESGSD I European Study on GSD I
G6Pase Glucose-6-phosphatase
GNG Gluconeogenesis
GSD Glycogen storage disease
MCT Medium-chain triglycerides
mFAO Mitochondrial fatty acid oxidation
UCCS Uncooked cornstarch
Introduction
To date there are 14 types of glycogen storage diseases (GSD),
which are classified according to enzyme or transporter defi-
ciency and organ distribution (Laforêt et al 2011). The hepatic
GSDs are inborn errors of glycogen synthesis or breakdown
clinically characterized by hepatomegaly, failure to thrive and
fasting intolerance, biochemically associated with
hypoglycaemia. Both endogenous glucose production (EGP)
and metabolic clearance rate of glucose determine blood glu-
cose concentration during fasting. Impairment of EGP may be
caused by decreased gluconeogenesis (GNG), decreased gly-
cogenolysis or a combination. Instead of discussing all hepatic
GSD types, this review focuses on lipid metabolism and mon-
itoring of dietary management in GSD type I and GSD type
III. These GSD types display important differences in both
pathophysiology and effects on lipid metabolism. During fol-
low-up, monitoring and prevention from significant long-term
morbidity is the rule in GSD I and GSD III, whereas to date,
the remaining subtypes (except GSD IV) are generally con-
sidered disorders without morbidity in adulthood.
GSD I is caused by a deficiency of the glucose-6-
phosphatase (G6Pase) complex (Bali et al 1993). G6Pase is
expressed in liver, kidney and intestine and plays a central role
in both glycogenolysis and GNG. This explains the severe
short-term fasting intolerance and hypoglycemia compared
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to patients with other hepatic types of GSD. Besides severe
nonketotic hypoglycemia, metabolic decompensation is char-
acterized by secondary biochemical abnormalities
(hyperlactacidaemia, hyperuricaemia and hyperlipidaemia).
Untreated patients classically displayed protruding abdomen
(hepatomegaly due to storage of glycogen and fat), short stat-
ure, truncal obesity, a rounded doll face, wasted muscles and
bleeding tendency. Two major subtypes of GSD I are recog-
nized. GSD type Ia (OMIM #232200) is caused by deficient
activity of the catalytic unit of G6Pase, whereas GSD Ib
(OMIM #232220) is caused by defect of the putative trans-
porter. In addition to the classical phenotype, GSD Ib patients
display recurrent bacterial infections, inflammatory bowel dis-
ease and thyroid auto-immunity, associated with neutropenia
and neutrophil dysfunction.
The remaining hepatic GSD types (0, III, VI, IX and XI)
are associated with fasting ketotic hypoglycemia and consid-
ered relatively mild compared to GSD I because GNG is
intact (Derks and Smit 2014). In these types of GSD, ketone
body (KB) concentrations reflect increased mitochondrial
fatty acid oxidation (mFAO), which is proceeded by activa-
tion of GNG and secondary endogenous proteolysis from
muscle tissue. GSD III (OMIM # 232400) is caused by a
deficiency of the debranching enzyme and phenotypically
classified as either type IIIa or type IIIb (Dagli et al 1993).
GSD IIIa patients (±85 %) display symptoms and signs due
to the enzyme deficiency in liver, skeletal muscle and heart,
whereas the remaining patients with GSD IIIb (±15 %) have
only liver-related phenotypes.
Dietary management in hepatic GSD is traditionally based
on the provision of exogenous carbohydrates to compensate
defective EGP, to achieve normoglycemia and to correct the
secondary metabolic effects as much as possible. In infant
GSD I patients, normoglycemia is maintained by frequent
(every 1.5–3 h) lactose free formula feeds enriched with
maltodextrin. In 1974 continuous nocturnal gastric drip-
feeding (CNGDF) via a nasogastric tube was introduced. It
was demonstrated that normoglycemia could be maintained
(Burr et al 1974; Greene et al 1976), secondary metabolic
alterations could be corrected and patients and parents were
able to sleep throughout the entire night. In 1984 uncooked
cornstarch (UCCS) was described for the first time in GSD
patients and developed as either a good alternative or addi-
tional strategy to maintain metabolic control (Chen et al 1984;
Smit et al 1984). Although UCCS may be introduced at
6 months of age, the tolerance may be reduced as a conse-
quence of lower pancreatic amylase activity until 1 year of age
(Hayde and Widhalm 1990). Both CNGDF and UCCS have
advantages and disadvantages and differ in many ways, like
the optimal age of introduction, duration of normoglycemia,
(no) need to wake up during the night, caloric content, glyce-
mic index, risk of technical failure with subsequent metabolic
risks, difficulty for parents and/or patients, invasiveness and
costs (Derks et al 2013). Dietary management in GSD III
patients follows similar principles of exogenous carbohy-
drates, but the additional role of increasing dietary protein is
recognized.
After dietary treatment became available, the phenotype of
GSD patients changed from mortality to morbidity and the
focus of attention moved towards (prevention of) long-term
complications (Moses 2002). For GSD I patients, these com-
plications mainly involve the liver (adenomas and their risks
of bleeding and secondary conformation to hepatocellular car-
cinoma), kidney (glomerular and tubular dysfunction, devel-
oping into renal insufficiency), intestine (GSD related enter-
opathy), growth (end length, body mass index (BMI)), ane-
mia, joints (gout) and bones (osteopenia and osteoporosis)
(Bali et al 1993). For GSD III patients, the liver (fibrosis,
cirrhosis and hepatocellular carcinoma), muscle (myopathy),
heart (cardiomyopathy), growth and bones deserve special
attention (Dagli et al 1993).
Monitoring of plasma lipids in hepatic GSD
In GSD I patients, triglyceride concentration are considered
the most useful parameter for chronic metabolic control. Like
blood glucose concentrations, lactate concentrations fluctuate
rapidly, liver enzymes are only slightly increased before initi-
ation of dietary management and rapidly normalize, and uric
acid concentrations can be influenced by allopurinol treat-
ment. In our personal clinical experience with GSD Ia pa-
tients, increasing triglyceride concentrations can reflect de-
creased metabolic control, for instance when young patients
outgrow their diet, by decreased compliance, during increased
growth in puberty or co-morbidity like hypothyroidism. Based
on an expert meeting as part of the European Study on GSD I
(ESGSD I), follow-up guidelines for the frequency of routine
laboratory investigations (including lipid profiles) are age de-
pendent: age 0–3 years every 2 month; 3–20 years every
3 months; adults every 6 months (Rake et al 2002b).
Cross-sectional cohort data on serum lipid concentrations
in GSD1 patients originate from the retrospective multicenter
ESGSD I, which included 231 GSD Ia and 57GSD Ib patients
(Rake et al 2002a). Hypercholesterolemia and triglyceridemia
were more common and more severe in GSD Ia patients com-
pared to GSD Ib patients. In adult GSD Ia (n=40) and GSD Ib
(n=4) patients hypercholesterolemia was noted in 43% versus
25 %, whereas 98 % versus 75 % displayed hypertriglyc-
eridemia. In this cohort, complications associated with hyper-
lipidaemia were rare; pancreatitis was reported in three pa-
tients and cholelithiasis in two patients. In the management
guideline paper originating from 2002, serum triglyceride
concentrations <6.0 mmol/L was included as a biomedical
target (Rake et al 2002b).
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In the ESGSD I the overall prevalence of liver adenomas
was 16 % and increased with age (Rake et al 2002a). More
recently, Wang and co-workers retrospectively characterized
the natural history and factors related to liver adenoma devel-
opment in GSD1a patients (Wang et al 2011). Patients were
stratified in two groups, i.e. patients with mean 5-year triglyc-
eride concentrations≤500 mg/dL (corresponding with
5.6 mmol/L) or>500 mg/dL, based on the consensus panel
discussion at the 2010 Association for Glycogen Storage Dis-
ease Conference. The authors reported significantly increased
adenoma progression in the latter group. By demonstrating the
association between a biomarker (i.e. increased triglyceride
concentrations) and outcome (i.e. increased prevalence of liv-
er adenomas), the authors added a new dimension.
In general, hyperlipidemia disappears with age and is
milder in the ketotic types of GSD, like GSD III. Bernier
et al studied the lipid profiles in 44 GSD III patients ranging
from 6 months to 30 years of age (Bernier et al 2008). They
demonstrated that the overall prevalences of hypercholester-
olemia (31 %) and hypertriglyceridemia (67 %) are lower than
in GSD I patients. Hypertriglyceridemia significantly de-
creased with increasing age in GSD III patients, the median
slope was −0.11 mmol/L per year.
Pathophysiology of lipid metabolism in hepatic GSD
From the point of pathophysiology, several important factors
contribute to the difference between GSD I and GSD III.
The fasted state in GSD I is characterized by intracellular
accumulation of glucose-6-phosphate with secondary
shunting to glycolysis and pentosephosphate route. Glycolysis
increases acetyl-CoA production and thereby lipogenesis and
ma l o ny l -CoA , t h e l a t t e r i n h i b i t i n g c a r n i t i n e
palmitoyltransferase I (CPT I), the rate-controlling step of
mFAO. Pharmacological inhibition of the glucose 6–phos-
phate transporter by S4048 induces hypoglycemia in wild
type mice, increased hepatic glycogen and triglyceride con-
tent, and a markedly enhanced hepatic lipogenic gene expres-
sion (van Dijk et al 2001). Human stable isotope studies re-
vealed that GSD Ia is associated with increased rates of de
novo lipogenesis and cholesterogenesis (Bandsma et al
2008). After administration of S4048 to several knock-out
mice models, the carbohydrate-response-element-binding
protein (but not the sterol-regulatory-element-binding protein
1c or liver X receptor α) was identified as an important mo-
lecular link mediating the induction of hepatic lipogenic gene
expression in GSD I, hence a potential target for pharmaco-
logical intervention in human patients (Grefhorst et al 2010).
Several metabolites of glycolysis (like glucose-6-phosphate
and fructose-2,6-bisphosphate) and the pentosephosphate
route (xylulose-5-phosphate) act as activators of the
carbohydrate-response-element-binding protein, illustrating
the complex interactions between intermediate metabolites
and transcription factors (for a recent review, see Oosterveer
and Schoonjans 2014).
Experimental data from stable isotope studies demonstrate
that EGP is age dependent and decreases relatively with body
weight (Bier et al 1977) and age (Huidekoper et al 2014).
Because in GSD I patients both glycogenolysis and GNG
are impaired, defective EGP and fasting intolerance are more
pronounced and lifelong, compared to the ketotic GSD types
like GSD III. In the latter group, hyperlipidemia is caused by
increased fatty acid flux from adipose tissue to the liver, as an
alternative source of energy bymFAO. The decreasing triglyc-
eride concentrations with increasing age goes in parallel with
decreasing EGP, reflecting improved fasting tolerance in age-
ing GSD III patients.
The role of dietary carbohydrate, fat and protein
First reports about dietary energy percentages of macronutri-
ents in GSD already originate from over four decades ago.
Kelsch and Oliver demonstrated that frequent high-
carbohydrate feeds improved most metabolic abnormalities
in a GSD I patient (Kelsch and Oliver 1969). Fernandes and
Pikaar recommended 50–70 and 40–50 % carbohydrates, 15–
35 and 30–40 % fat and 15 and 20 % protein, in patients with
GSD I and ketotic subtypes, respectively (Fernandes and
Pikaar 1969). Fernandes also studied the effects of different
disaccharides on blood lactate concentrations and these stud-
ies are the experimental base of dietary restrictions of fructose,
lactose and saccharose (Fernandes 1974).
Since then, between treatment centers worldwide, major
differences have arisen in the practical effectuation of dietary
management in GSD (type I). Examples include the type of
nocturnal management (UCCS versus CNGDF), the timing of
the introduction of UCCS (at which age?), the methods by
which exogenous carbohydrates are given and the extent of
dietary restrictions of fructose, lactose and saccharose. Recent
data from a meta-analysis of three studies suggest that UCCS
was associated with significantly higher plasma cholesterol
concentrations compared to CNGDF (Shah and O’Dell
2013). There was no significant difference in plasma triglyc-
eride concentrations between these treatments. The difference
in lipid profiles between UCCS and heat-treated modified
starch has not been systematically studied. In general, these
examples emphasize the need of international detailed
(dietary) data collection and practical management guidelines
appreciating that dietary management in hepatic GSD needs to
be individually tailored.
Next to the recommendations about dietary energy
percentages of macronutrients, data from stable isotope stud-
ies on EGP in humans are helpful to estimate the absolute
carbohydrate requirements. Taking into account, that the
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theoretical EGP decreases with age, the exogenous glucose
requirements for GSD I patients can be estimated with regres-
sion formulas derived from these tracer studies. The historical
studies by Bier and co-workers have generated a regression
formula using body weight as a variable; recently Huidekoper
and co-workers generated a regression formula based on age
(Fig. 1). Compared to the latter method, the historical method
may overestimate carbohydrate requirements because it obvi-
ously does not correct for overweight/obesity. At some time
points in childhood, the calculation based on age is 25–30 %
lower compared to the other method. In addition, both
methods share another risk of overtreatment because the tracer
studies have been performed in healthy overnight fasted con-
trol subjects, a situation different from the perturbed glucose
homeostasis in GSD I patients. Experimental data in GSD Ia
patients indicate that in vivo EGP is not completely absent and
may reach ~60 % of normal (Huidekoper et al 2010). The
mechanism is not understood, theoretically, residual in vivo
glucose-6-phosphatase-α activity next to alternative glyco-
genolysis by (muscle) glucose-6-phosphatase-β and/or the
α-glucosidase pathway may contribute to whole body EGP
in GSD Ia patients.
Figure 2 presents total energy expenditure and EGP in
childhood, both expressed in kcal/day. The graph illustrates
that the caloric intake by replacement of EGP declines from 60
to 30 % in the first 3 years of life. This may indicate that
especially in (early) childhood, dietary management is char-
acterized by a delicate balance between undertreatment (with
hypoglycemias, poor metabolic control and risk of long-term
complications) and overtreatment (with the risk of rebound
hypoglycemias, peripheral body fat storage and obesity). In
the European Study on GSD I, about 25 % of the GSD Ia and
33 % of the GSD Ib patients under 20 years of age display
BMI above the 90th percentile, interestingly highest preva-
lence was observed in young patients between 2 and 5 years
of age.
From a practical point of view, increasing one macronutri-
ent (carbohydrates) without affecting the second (protein) in-
evitably lowers fat intake. Given the carbohydrate deficiency
and hyperlipidemia in GSD I and GSD III, increasing dietary
fat is somewhat counterintuitive. However, there are two pos-
itive reports about high-fat diets in GSD III patients. The com-
bination of synthetic ketone bodies, 2:1 ketogenic diet and
high-protein was associated with reversal of hypertrophic car-
diomyopathy in a 2-months-old GSD IIIa patient
(Valayannopoulos et al 2011). In two 7- and 5-year-old sib-
lings, a high-carbohydrate diet was isocalorically replaced by
a high fat (60 %) and high protein (25 %, which remained
fairly constant), low-carbohydrate (15 %) diet, associated with
reversal of hypertrophic cardiomyopathy (Brambilla et al
2014).
Several case reports describe the effects of medium chain
triglycerides (MCT) in GSD I and III (Fernandes and Pikaar
1969; Cuttino et al 1970; Nagasaka et al 2007; Hanou et al
2008; Burns et al 2009; Das et al 2010; Bernstein et al 2010;
El-Gharbawy et al 2014). In summary, laboratory parameters
Fig. 1 Two regression models to calculate endogenous glucose
production, based on body weight (grey, by Bier et al 1977) and age
(black, by Huidekoper et al 2014). The grey line represents the EGP
regression line according to Bier. Reference values for body weight in
boys were retrieved from the World Health Organization and the Centers
for Disease Control and Prevention, below 2 years and after 2 years of
age, respectively. EGP (expressed in mg/min) is calculated as: 0.0014x3–
0.214x2 + 10.411x–9.084, with [x] representing body weight in kg. The
black line represents EGP regression line according to Huidekoper. EGP
(expressed in mg/kg/min) is calculated as: 6:50 × 2.72−0.145×Z + 1.93,
with [z] representing age in years
540 J Inherit Metab Dis (2015) 38:537–543
of metabolic control (triglyceride concentrations in GSD I;
transaminases and CK in GSD III) decrease after MCT-sup-
plementation, demonstrating that hyperlipidemia is
carbohydrate-induced in GSD I. However, an overall interpre-
tation with conclusions and management advise based on the-
se observations is complicated by differences in age, GSD
type and severity (type of mutations) of the disorder, relative
and absolute quantities of macronutrients, MCT-sources, indi-
cations for MCT-treatment, outcome-parameters, the absence
of long-term clinically relevant follow-up data and the possi-
bility of selection bias, unfavourable cases not being reported.
There are no experimental data to substantiate whether long-
term dietary MCTmay cause liver adenoma and hepatocellular
carcinoma. The development of hepatic tumors is enhanced by
a high fat enriched diet in liver-specific GSD I deficient mice
(Rajas et al 2014), but it is not mentioned whether this depends
on the type of fat, i.e. MCT versus long-chain triglycerides. In
GSD I cytoplasmatic Acetyl-CoA accumulation and subse-
quent malonyl-CoA formation functionally inhibit mFAO at
the level of CPT I. MCT are absorbed via the portal vein and
the released free fatty acids enter mFAO without the carnitine
shuttle. The beta-oxidation generates intramitochondrial
Acetyl-CoA for direct ketogenesis. It can be hypothesized that
increased ketogenesis by MCT decreases the metabolic clear-
ance rate of glucose in GSD I patients, although the exact
molecular mechanism is still unknown.
MCT can be supplied by naturally occurring dietary prod-
ucts, medical dietary supplements, or pharmaceutically
(triheptanoin). For all methods, the potential risk of glycerol
overload towards impaired GNG in GSD I patients is un-
known. Triheptanoin is a medium-chain triglyceride of 7-
carbon fatty acids observationally studied in patients with
long-chain mitochondrial fatty acid oxidation disorders.
Besides the ease of use, the anapleurotic effect of triheptanoin
GSD Ia could be beneficial.
The role of dietary protein in GSD I has not systematically
been studied and has recently been reviewed for GSD III
(Derks and Smit 2014).
Discussion and future directions
In summary, hepatic GSD underscores the intimate relations be-
tween carbohydrate and lipid metabolism. Hyperlipidemia is
most pronounced and often permanent in GSD I, in whom the
intrahepatic degree of metabolic control is reflected by blood
lipid concentrations. Hypertriglyceridemia is associated with
pancreatitis and liver adenomas in GSD I patients. In ketotic
GSD patients, hyperlipidemia reflects lipolysis from extrahepatic
sources, associated with the age-dependent fasting intolerance.
Like often in rare diseases, medical emergencies in individ-
ual patients initiated (dietary) interventions and generated new
hypotheses. Future experimental animal studies and well-
designed collaborative dietary intervention studies are neces-
sary to improve our understanding about manipulations in mac-
ronutrients, like the restrictions of simple sugars, traditional
versus heat-treated modified starch, the role of protein, MCT-
treatment, triheptanooin and the ketogenic diet in GSD type III.
International patient registries will be necessary to study out-
come and the effects of (elements of) dietary management.
In the next decades, dietary management of GSD patients
will be individualized more than ever, integrating personal met-
abolic and genetic data to optimize metabolic control. Contin-
uous glucose monitoring systems are used in GSD patients in
the real life situation to improve dietary management and there-
by parameters of metabolic control, including the lipid profile
Fig. 2 Daily total energy
expenditure (black) and
endogenous glucose production
calculated by age (grey), both
expressed in kcal/day, according
to age. Reference values for total
energy expenditure (expressed as
kcal/kg/day) in boys were
retrieved from the Joint FAO/
WHO/UNU Expert Consultation
on Human Energy Requirements.
Reference values for body weight
in boys were retrieved from the
World Health Organization and
the Centers for Disease Control
and Prevention, below 2 years
and after 2 years of age,
respectively. EGP was calculated
according to Huidekoper
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(Hershkovitz et al 2001;White and Jones 2011; Kasapkara et al
2014). Nowadays, the most modern (and expensive) devices
alarm at low glucose levels, significantly improving safety.
Near infra red spectroscopy is a promising technique for non-
invasive measurement of blood glucose (Xue et al 2014) and
the integration of this technique in the glucose monitoring sys-
tems would add new dimensions to the safety and acceptability
of dietary management of GSD patients.
The definition of the metabolic syndrome and their criteria
has been revised several times, leading to multiple definitions
in current use. However, the general concept is that patients
have a combination of conditions, among which are insulin
resistance or hyperglycemia, hyperlipidemia, hypertension
and obesity. Regardless of which definition, GSD I patients
meet some of the criteria applied. Currently there are conflict-
ing experimental data (Ubels et al 2002; Bernier et al 2009)
and no convincing epidemiological data substantiating strong
associations betweenmetabolic syndrome, type 2 diabetes and
GSD. Close clinical monitoring for cardiovascular diseases,
chronic kidney disease and diabetes in ageing GSD patients
(regardless what subtype) seems to be justified, because these
disorders share many metabolic pathways (Rajas et al 2013).
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